Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend
Regions Seek To Bolster Domestic Production Capacity As Weaknesses Exposed
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
You may also be interested in...
Sandoz CEO Richard Saynor has spoken of the ways in which the pandemic has changed the industry, from supply chains to working patterns, and makes predictions for the years ahead.
Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.
A medicines manufacturing “road map” set out by Australia’s government has the backing of the local off-patent industry.